Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Asian J Androl. 2022 Nov-Dec;24(6):671-674. doi: 10.4103/aja2021116.
Clinical staging, Gleason score, and prostate-specific antigen (PSA) have been accepted as factors for evaluating the prognosis of prostate cancer (PCa). With the in-depth study of iron metabolism and the development of multiparametric magnetic resonance imaging technology, we used q-Dixon magnetic resonance imaging (MRI) to measure the iron content of the PCa patients' lesions, and used enzyme-linked immunosorbent assay (ELISA) to measure the iron metabolism indicators in the patients' serum samples, combined with the patients' postoperative clinical data for analysis. We found that the serum indexes were correlated with the T2 star values, International Society of Urological Pathology (ISUP) grade, and pathological classification in PCa patients (all P < 0.001) but not in benign prostatic hyperplasia (BPH) patients (all P > 0.05). The utilization of q-Dixon-based MRI and serum indexes allows the noninvasive measurement of iron content in prostate lesions and the assessment of differential iron metabolism between PCa and BPH, which may be helpful for evaluating the prognosis of PCa.
临床分期、格里森评分和前列腺特异性抗原（PSA）已被接受为评估前列腺癌（PCa）预后的因素。随着对铁代谢的深入研究和多参数磁共振成像技术的发展，我们使用 q-Dixon 磁共振成像（MRI）测量 PCa 患者病变的铁含量，并使用酶联免疫吸附试验（ELISA）测量患者血清样本中的铁代谢指标，结合患者术后临床资料进行分析。我们发现，血清指标与 PCa 患者的 T2 星值、国际泌尿病理学会（ISUP）分级和病理分类相关（均 P < 0.001），但与良性前列腺增生（BPH）患者无关（均 P > 0.05）。q-Dixon 基于 MRI 和血清指标的应用允许对前列腺病变中铁含量进行无创测量，并评估 PCa 和 BPH 之间的差异铁代谢，这可能有助于评估 PCa 的预后。
